CompoAtlas

Beauty' hair woman

Food supplement declared in France, declaration No 2023-1-1251, decision dated 25 January 2023

Beauty' hair woman, from NFB Healthcare, is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Eruca vesicaria 110 mg per day, Bambusa bambos 70 mg per day, Vaccinium myrtillus 50 mg per day, Cannabis sativa 11 mg per day, Pantothenic acid (vitamin B5). 1 point in its composition requires a check (prohibited substance, dose or novel food).

Brand
not provided
Food business operator placing the product on the market
NFB Healthcare
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Capsule
Daily dose
2 gélules par jour
Directions for use
Prendre 2 gélules par jour avec un verre d’eau.
Intended populations
Women
Not recommended (according to the manufacturer)
Adolescents (under 18), Breastfeeding women, Children (under 12), Young children (aged 1 to 3), Pregnant women, Infants (under 1 year), Children (under 6), Children (under 10)
Objectives stated by the manufacturer (these are not authorised claims)
Hair and nails

Declaration 314949, procedure Article 15. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Eruca vesicaria L. Cav.Parties aériennesExtrait sec hydroalcoolique110 mg
Bambusa bambos (L.) VossExsudatExtrait sec aqueux70 mg
Vaccinium myrtillus L.BaiePoudre (de plantes séchées ou broyées)50 mg
Cannabis sativa L.Graine (huile)Pression à froid11 mg

Other active ingredients

NamePer day
Méthioninenot declared
Méthylsulfonate de méthanenot declared
Acétylcystéinenot declared

Vitamins and minerals

Compl'Alim does not publish vitamin and mineral doses. The references below help you read the product label: EFSAEuropean Food Safety Authority. safety limit for adults and maximum dose set in France per product (Order of 9 May 2006, not revised since November 2006).

Declared formNutrientEFSA limit, adults Maximum dose in France
D-pantothenate, calciumPantothenic acid (vitamin B5)no limit (insufficient data)dose annulled by the French Council of State in 2011
D-biotinBiotin (vitamin B8)no limit (insufficient data)dose annulled by the French Council of State in 2011
pteroylmonoglutamic acidFolate (vitamin B9)1,000 µg200 µg
nicotinamideNicotinamide (vitamin B3)900 mg54 mg
selenium enriched yeastSelenium255 µg50 µg
thiamin hydrochlorideVitamin B1 (thiamine)no limit (insufficient data)dose annulled by the French Council of State in 2011
riboflavinVitamin B2 (riboflavin)no limit (insufficient data)dose annulled by the French Council of State in 2011
pyridoxine hydrochlorideVitamin B612 mg2 mg
D-alpha-tocopheryl acid succinateVitamin E300 mg30 mg
zinc bisglycinateZinc25 mg15 mg

Additives

E414, E464

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Label warnings

Réservé à l’adulte. Déconseillé chez les femmes enceintes et allaitantes.

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Vaccinium myrtillus L.
    Read the warning, when it applies and the studies cited

    BILBERRY - VACCINIUM MYRTILLUS - Buccal

    Route of administration: Buccal (Blumenthal et al. 2000)

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 30 January 2026

    BILBERRY - VACCINIUM MYRTILLUS - Oral

    Route of administration: Oral (Blumenthal et al. 2000)

    Cautions and warnings

    Condition of application: Relief of diarrhea.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Condition of application: Slowing the progression of disorders of the eye and to relieve symptoms related to non-complicated CVI.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.

    Health Canada monograph dated 25 October 2024

  • Méthylsulfonate de méthane
    Read the warning, when it applies and the studies cited

    MSM

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms worsen.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Known adverse reactions

    When using this product you may experience gastrointestinal discomfort/disturbances (Kim et al. 2005).

    1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).

    Health Canada monograph dated 19 December 2025

  • Acétylcystéine
    Read the warning, when it applies and the studies cited

    N-ACETYL-L-CYSTEINE

    Route of administration: Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have kidney stones (Fauci et al. 1998; Mårtensson et al. 1990).

    Sources cited by Health Canada (2)
    • Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DI, Hauser SL and Longo DL, editors. Harrison's Principles of Internal Medicine, 14th edition. Toronto (ON): McGraw-Hill Health Professions Division; 1998.
    • Mårtensson J, Denneberg T, Lindell Å, Textorius O. Sulfur amino acid metabolism in cystinuria : A biochemical and clinical study of patients. Kidney International 1990;37:143-149. PubMed

    Contraindications

    Do not use if you are taking antibiotics or nitroglycerin (Repchinsky 2008; Cederlund and Märdh 1993; Parry and Neu 1977; Ardissino et al. 1997).

    Sources cited by Health Canada (4)
    • Ardissino D, Merlini PA, Savonitto S, Demicheli G, Zanini P, Bertocchi F, Falcone C, Ghio S, Marinoni G, Montemartini C, Mussini A. Effect of transdermal nitroglycerin or N- acetylcysteine, or both, in the long-term treatment of unstable angina pectoris. Journal of the American College of Cardiology 1997;29(5):941-947. PubMed Randomised trial
    • Cederlund H, Märdh PA. Antibacterial activities of non-antibiotic drugs. Journal of Antimicrobial Chemotherapy 1993;32:355-365. PubMed Review article
    • Parry MF, Neu HC. Effect of N-acetylcysteine on antibiotic activity and bacterial growth in vitro. Journal of Clinical Microbiology 1977;5(1);58-61.
    • Repchinsky C, editor. Compendium of Pharmaceuticals and Specialties. The Canadian Drug Reference for Health Professionals. Ottawa (ON): Canadian Pharmacists Association; 2008.

    Health Canada monograph dated 19 December 2025

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Beauty' hair woman: composition and regulation”, https://compoatlas.com/en/supplements/products/314949-beauty-hair-woman, updated 15 November 2026.

List recorded in 2023. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line